Allogeneic cell therapy production trends: driving tomorrow’s success

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Allogeneic cell therapy production trends: driving tomorrow’s success

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Allogeneic cell therapies have some clear advantages over autologous cell therapies including cell source, cost to manufacture, process success rate, speed, and availability of therapy to patients.

As more and more therapies come out of the lab and head for the clinic, the process and solutions required to bring these drug products safely and quickly to market must keep pace.

Join us for this CGTI Live 30 to hear from Tom Bongiorno, PhD, field application scientist at Corning Life Sciences, about current trends in allogeneic stem cell therapy production, including proven and emerging technology platforms, optimized surface selection, and process best practices.

Review current trends in allogeneic stem cell therapy production
Overview of current technology platforms, including key benefits for each platform and their role within optimized workflows
Introduction to new technology platforms and overview of features
Surface selection guidance aligned with project goals
Workflow process best practices

Tom Bongiorno

Field Application Scientist at Corning Life Sciences

Tom Bongiorno is a field application scientist at Corning Life Sciences, covering the central United States. He has expertise in stem cell therapy, bioprocessing, media development, and cryopreservation. Tom holds a PhD in bioengineering from the Georgia Institute of Technology and a BS in mechanical engineering from the University of Norte Dame.